NCT06479655

Brief Summary

The primary aim of this clinical trial is to compare the effectiveness of fentanyl vs morphine as analgosedation in mechanically ventilated adult patients in the ICU. This study also aims to compare the outcomes of patients between the two groups. The main questions it aims to answer are :

  1. 1.Does propofol and fentanyl infusion as analgo-sedation achieve targeted sedation score at 12 and 24 hours compared to propofol and morphine infusion in mechanically ventilated adult patients in the intensive care unit (ICU)?
  2. 2.Is there a difference between the proportion of patients requiring rescue sedation dose between the fentanyl and morphine groups?

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
116

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started Jul 2024

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 14, 2024

Completed
14 days until next milestone

First Posted

Study publicly available on registry

June 28, 2024

Completed
17 days until next milestone

Study Start

First participant enrolled

July 15, 2024

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 15, 2025

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2025

Completed
Last Updated

October 6, 2025

Status Verified

September 1, 2025

Enrollment Period

1.3 years

First QC Date

June 14, 2024

Last Update Submit

September 30, 2025

Conditions

Outcome Measures

Primary Outcomes (2)

  • RASS score at 12 and 24 hours

    To determine the proportion of patients achieving the targeted sedation guided by RASS score at 12 and 24 hours in both fentanyl and morphine group.

    24 hours from study drug initiation

  • Rescue sedation doses

    To determine the proportion of patients requiring rescue sedation doses between fentanyl and morphine group

    24 hours from study drug initiation

Secondary Outcomes (3)

  • Duration of mechanical ventilation

    90 Days

  • Length of ICU stay

    90 days

  • 14 days mortality rate

    14 days from randomization

Study Arms (2)

Fentanyl

ACTIVE COMPARATOR

Intravenous fentanyl infusion 0.5 - 1 mcg/kg/hr

Drug: Fentanyl

Morphine

ACTIVE COMPARATOR

Intraveous morphine infusion 0.05 - 0.1 mg/kg/hr

Drug: Morphine

Interventions

Intravenous fentanyl infusion with dilution of 10mcg/ml

Fentanyl

Intravenous morphine infusion with dilution 1mg/ml

Morphine

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age \>18 years old
  • Patients who are expected by the ICU team to require invasive mechanical ventilation in ICU for at least more than 24 hours and for whom the ICU team decides to initiate continuous infusion of sedation
  • A patient who was ventilated and sedated not more than 12 hours before ICU admission.

You may not qualify if:

  • Patients with chronic use of narcotics
  • Patients with chronic liver failure or end-stage renal failure
  • Patients with severe chronic neurocognitive dysfunction
  • Patients with drug overdose
  • Patients with a known allergy to either morphine or fentanyl
  • Patients who are receiving neuromuscular blockers
  • Patients who are pregnant
  • Patients who are diagnosed to have severe traumatic brain in

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hospital Universiti Sains Malaysia

Kota Bharu, Kelantan, 16150, Malaysia

RECRUITING

MeSH Terms

Interventions

FentanylMorphine

Intervention Hierarchy (Ancestors)

PiperidinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsMorphine DerivativesMorphinansOpiate AlkaloidsAlkaloidsHeterocyclic Compounds, Bridged-RingHeterocyclic Compounds, 4 or More RingsHeterocyclic Compounds, Fused-RingPhenanthrenesPolycyclic Aromatic HydrocarbonsPolycyclic Compounds

Central Study Contacts

Mohd Zulfakar Mazlan Dr, MBBS

CONTACT

Saravana Raj Joseph, MD

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Model Details: Randomized control trial, two arms
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Prof Dr

Study Record Dates

First Submitted

June 14, 2024

First Posted

June 28, 2024

Study Start

July 15, 2024

Primary Completion

November 15, 2025

Study Completion

December 30, 2025

Last Updated

October 6, 2025

Record last verified: 2025-09

Data Sharing

IPD Sharing
Will not share

Locations